

KINAXO Biotechnologies Announces Renewal of Agreement with Janssen Pharmaceutica NV

Martinsried, Germany, October 28, 2009. KINAXO Biotechnologies announced today that its agreement with Ortho Biotech Oncology Research & Development, a division of Janssen Pharmaceutica N.V., Beerse, Belgium, has been extended. Under the extended agreement, KINAXO will apply its advanced chemical proteomics and phosphoproteomics services to enable comprehensive cellular mode of action analyses of oncology compounds under development.

Detailed knowledge of a compound's cellular mode of action is a key issue in any drug development program. The main advantage of Kinaxo's technology is that it provides a comprehensive picture of a compound's cellular interactions and its influence on posttranslational modifications.

About KINAXO

KINAXO Biotechnologies GmbH is a privately-held biotechnology company based in Munich/ Martinsried, Germany. KINAXO has several ongoing collaborations with major pharmaceutical companies. Our services are routinely applied to decrease drug development times and improve therapeutic strategies. KINAXO's technology portfolio Cellular Target Profiling[®], KinAffinity[®] and PhosphoScout[®] provides customized solutions to support our clients' projects, such as lead compound optimization, clinical candidate selection, off-target toxicity assessment, target deconvolution or drug reprofiling.

Contact: Dr. Jutta Fritz, MBA, Head of Technology and Business Development,
KINAXO Biotechnologies GmbH, Email: info@kinaxo.de, Phone +49 89 4613363-22